DESTINY-Lung03: T-DXd Confirms Activity in HER2-Overexpressing NSCLC, but Triplet Therapy Falls Short
oncodaily - DESTINY-Lung03 Part 1 provides an important signal for the treatment of HER2-overexpressing non-small cell lung cancer (NSCLC). The study confirms that trastuzumab deruxtecan (T-DXd) monotherapy has clinically meaningful activity in […]
AI Summary: DESTINY‑Lung03 data confirmed trastuzumab deruxtecan has tangible activity in HER2‑overexpressing non‑small‑cell lung cancer, producing notable responses. Attempts to escalate to triplet regimens failed to add benefit, prompting a reality check on combination complexity and the need for sharper biomarkers rather than more drugs.
Related Stories
Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 7 days
Teclistamab shows survival benefit prompting earlier use discussions / 21 days
CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 2 months
Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 2 months
Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 2 months
Antoni Ribas receives AACR‑Margaret Foti Award for leadership / 3 months
Romiplostim reduces chemotherapy‑induced thrombocytopenia and prevents recurrence / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Olfaction, Healthcare Finance, FDA, Drug Pricing and look for the RSS link.
StackHealth Time Machine